Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATFurniture, Fixtures and OtherLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

CytomX Therapeutics (CTMX) Accumulated Depreciation & Amortization: 2014-2024

Historic Accumulated Depreciation & Amortization for CytomX Therapeutics (CTMX) over the last 2 years, with Dec 2024 value amounting to $16.2 million.

  • CytomX Therapeutics' Accumulated Depreciation & Amortization rose 10.51% to $16.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $59.1 million, marking a year-over-year increase of 8.85%. This contributed to the annual value of $16.2 million for FY2024, which is 10.51% up from last year.
  • CytomX Therapeutics' Accumulated Depreciation & Amortization amounted to $16.2 million in Q4 2024, which was up 10.51% from $14.7 million recorded in Q4 2023.
  • In the past 5 years, CytomX Therapeutics' Accumulated Depreciation & Amortization registered a high of $16.2 million during Q4 2024, and its lowest value of $11.4 million during Q4 2020.
  • For the 3-year period, CytomX Therapeutics' Accumulated Depreciation & Amortization averaged around $15.1 million, with its median value being $14.7 million (2023).
  • Data for CytomX Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY increased of 26.25% (in 2020) over the last 5 years.
  • Quarterly analysis of 5 years shows CytomX Therapeutics' Accumulated Depreciation & Amortization stood at $11.4 million in 2020, then climbed by 21.06% to $13.8 million in 2021, then rose by 3.91% to $14.4 million in 2022, then rose by 2.19% to $14.7 million in 2023, then climbed by 10.51% to $16.2 million in 2024.
  • Its last three reported values are $16.2 million in Q4 2024, $14.7 million for Q4 2023, and $14.4 million during Q4 2022.